“How to Launch an Industry”, created and hosted by my friends, Dr. Jahan Marcu and Dr. Nigam Arora, is one of the most intelligent and creative podcasts I’ve encountered about the psychedelics and cannabis industries. I was a recent guest on the June 14 episode, “Profit and Laws”.
Category: In the Media
Listen to an in-depth conversation about the challenges facing hemp and CBD businesses with Rod Kight and Scott Hawksworth of The CBD Guide.
I recently discussed hemp-derived delta-8 THC with attorneys Matt Lewis and Morgan Davis of The CBD Association, a 501(c)6) nonprofit trade association that promotes strong and viable CBD and cannabinoid industries in the United States and internationally. A video of our conversation is embedded in this post.
The HIA recently hosted a video webinar to provide information about the case. I discussed the litigation with my colleague and friend, Shane Pennington, of the Vicente-Sederberg law firm. The hour-long webinar was moderated by HIA Executive Director Jody McGinniss. You can watch it here.
Happy 420 from Rod and Ashley Kight (and Ripley)!
Rod recently took part in a legal and scientific discussion of certificates of analysis and Total THC with Abundant Labs and RiskScout. Watch the video here.
In this podcast, hosted by John Bruford of CBD-Intel, Rod discusses cannabis regulation in the US, including the new Administration, the FDA, state laws, and related topics.
In this video podcast, Rod discusses the intersection of law and science that arises from cannabis use and driving. Traditional DUI tests are primarily oriented towards detecting alcohol impairment. Do these tests work for cannabis impairment? If not, is it possible to create cannabis-specific testing protocols, and accompanying laws and regulations, that accurately measure impairment while not unjustly criminalizing unimpaired cannabis users?
In this video, Rod discusses delta-8 THC, CBD and cannabis in Europe and Mexico, the role of international treaties in cannabis reform, California’s Proposition 65, and the FDA’s position on CBD, among other cannabis issues.